Program
GENSCI122
A development code. Also written as “GenSci122 tablet 50mg” and “GenSci122 tablet 250mg”.
Its studies are led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 10 open or running | phase 1since Jan 2, 2025 | Jan 2, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 2, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT06772415 · 163 enrolled · China
- Nov 17, 2026Phase 1 study terminatedStudy stoppedNCT06772415 · “The sponsor adjusted its research and development strategy”
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06772415Advanced Solid Tumor · China | 1 | Terminated | Oct 22, 2026 | 163 |
How it is read
Names in the registry
- “GenSci122 tablet 50mg”, 1 entry
- “GenSci122 tablet 250mg”, 1 entry
Codes read as this program: GENSCI122.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.